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Anionic glycolipids related to glucuronosyl-
diacylglycerol inhibit protein kinase Akt†
Maria Vetro,a Barbara Costa,b Giulia Donvito,b Noemi Arrighetti,c Laura Cipolla,b
Paola Perego,*c Federica Compostella,a Fiamma Ronchettia and Diego Colombo*a
New glucuronosyldiacylglycerol (GlcADG) analogues based on a 2-O-β-D-glucopyranosyl-sn-glycerol
scaﬀold and carrying one or two acyl chains of diﬀerent lengths have been synthesized as phosphatidyl-
inositol 3-phosphate (PI3P) mimics targeting the protein kinase Akt. The Akt inhibitory eﬀect of the pre-
pared compounds was assayed using an in vitro kinase assay. The antiproliferative activity of the
compounds was tested in the human ovarian carcinoma IGROV-1 cell line in which we found that two of
them could inhibit proliferation, in keeping with the target inhibitory eﬀect.
Introduction
Glucuronosyldiacylglycerols (GlcADGs, Fig. 1) are unusual
acidic glycoglycerolipids found in bacteria,1 fungi,2 algae3 and
in some higher plants such as Arabidopsis thaliana and rice,4
and only very recently their first synthesis has been reported.5
Their presence in these photosynthetic organisms seems to be
related to conditions of reduced phosphorous availability in
which they replace phospholipids for their biological func-
tions.4,6 GlcADGs participate in this lipid remodelling as the
better-known anionic sulfolipids, sulfoquinovosyldiacylglycerols
(SQDGs, Fig. 1),7,8 sharing also the same biosynthetic pathway
which requires a common SQDG synthase.4 In contrast to
GlcADGs, in the last few years both natural and synthetic sulfo-
quinovosylacylglycerols have been tested for their antitumor,
antiviral, anti-inflammatory, immunosuppressive and other
bioactivities.9–13 This prompted us to prepare some SQDG ana-
logues (Fig. 1) based on 2-O-β-D-glucosylglycerol, which were
tested as inhibitors of tumor-promoters in cancer prevention
studies.14a,15 These unnatural sulfolipids, similar to other
glucose-based compounds,16 display a structure which can be
related to that of 3-phosphorylated phosphatidylinositol (PI3P,
Fig. 1), one of the natural phospholipids involved in the regu-
lation of specific lipid-binding domains (e.g. PH, FYVE or PX)
in phosphatidylinositol-3-kinase (PI3K) eﬀector proteins.17a–d
Thus they are currently investigated as potential inhibitors of
protein kinase B (PKB or Akt),18 a kinase involved in sustain-
ing multiple aggressive features of tumor cells such as inva-
sion capability and reduced sensitivity to antitumor agents.19
PI3P and the other 3-phosphorylated phosphatidylinositols,
i.e. PI(3,4,5)P3 and PI(3,4)P2, are generated by PI3K and, at the
plasma membrane, they can bind the pleckstrin homology
(PH) domain promoting kinase activation.17a,20
Fig. 1 Structures of PI3P, related natural anionic glycolipids and syn-
thetic analogues.
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Many proteins with the PH domain are known, but only a
few of them are regulated by the direct binding of 3-phospho-
inositides.17a For this reason, even if diﬀerent types of small
molecules have been synthesized as Akt inhibitors (e.g. ATP
mimetics and allosteric inhibitors), PH binders (such as
perifosine, 3-DPI and 3-DPIEL) are thought as more selective
potential Akt inhibitors.19,21,22
Here we describe the synthesis of the new glucuronosyldi-
acylglycerol (GlcADG) analogues 1a,b and 2a,b, carrying acyl
chains which diﬀer in length and number (Fig. 1) as PI3P ana-
logues that could target the Akt pleckstrin homology domain.
They maintain the same 2-O-β-D-glucopyranosyl-sn-glycerol
scaﬀold of SQDG analogues but a diverse anionic group is
installed at position 6 of the sugar moiety (COO− vs. SO3
−) for
interaction with the PI3P binding pocket of the PH domain,
which is characterized by positively charged residues.22 At the
same time the glucuronides 3a,b (Fig. 1) have been prepared
as simplified anionic models for binding the PH domain. The
biological activity of selected compounds is also presented as
inhibitory activity against Akt, both in an isolated enzyme
system and in an ovarian carcinoma cell line.
Results and discussion
Chemistry
Synthesis of monoesters 1a,b. Compounds 1a,b were
eﬃciently prepared starting from the known 2-O-(2′,3′,4′,6′-
tetra-O-acetyl-β-D-glucopyranosyl)-sn-glycerol23a,b (Scheme 1).
Its Pseudomonas cepacia lipase (LPS) mediated transesterifica-
tion in an organic solvent, by means of a procedure already
used for similar substrates employing 2,2,2-trifluoroethyl (TFE)
esters as acyl carriers,24 allowing selective introduction of the
desired acyl chain (octadecanoyl or decanoyl) at C-1 of the sn-
glycerol moiety in good yields. The configurations of the
obtained 4a,b were confirmed by chemical correlation with
known compounds24 (vide infra). After conventional tritylation
of the remaining primary free hydroxyl, the obtained fully pro-
tected glucosylglycerols 5a,b were converted with reasonable
yields into the fully deacetylated compounds 6a,b by treatment
with hydrazine hydrate in aqueous ethanol for selective
removal of the sugar acetyls.25 Selective TEMPO oxidation of
the glucose primary hydroxyl group yielded 7a,b which were
finally transformed into the desired compounds 1a,b by treat-
ment with an acidic resin in dichloromethane.
Configuration assignment of compounds 4a,b. Compound
4a was transformed into the 3-O-acetyl derivative by acetic
anhydride/pyridine treatment. The obtained compound was
identical to the known 1-O-octadecanoyl-3-O-acetyl-2-O-
(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-sn-glycerol,24 con-
firming the 2S configuration of compound 4a. As the enzy-
matic transesterifications employed to obtain the monoesters
4a and 4b diﬀered just in the acyl carrier used, only the con-
figuration of compound 4a was assigned, assuming the same
2S configuration for compound 4b also.
Synthesis of diesters 2a,b. The glucuronide diester 2a was
obtained14b by regioselective TEMPO oxidation of the primary
hydroxyl of the known14a 1,3-di-O-octadecanoyl-2-O-β-D-gluco-
pyranosyl-sn-glycerol 8a. Similarly, the didecanoate 8b,
obtained from the known 2-O-(2,3,4,6-tetra-O-chloroacetyl-β-D-
glucopyranosyl)-sn-glycerol14c (see Experimental), was eﬃcien-
tly oxidized to 2b (Scheme 2).
Synthesis of glucuronides 3a,b. Known glucuronides 3a26
and 3b27 (see ESI†) were obtained in good yields by regioselec-
tive TEMPO oxidation26 of decyl β-D-glucopyranoside28 and
commercial octyl β-D-glucopyranoside, respectively.
Cell free evaluation of Akt inhibition
The prepared glucuronides, with the exception of compound
2a that was not soluble in DMSO, were tested for in vitro
inhibitory activity against Akt (Akt1), using an in vitro ELISA
kinase assay.
Fig. 2 shows the eﬀects of compounds 1a–b, 2b, 3a–b,
tested at five diﬀerent (1, 10, 50, 100 and 500 µM) concen-
trations compared to the alkylphospholipids (ALPs) miltefo-
sine (general inhibitor of the PI3K/Akt pathway) and perifosine
(Akt inhibitor targeting the PH domain)29 and the surfactant
sodium dodecyl sulfate (SDS).
The results show that the Akt1 activity is poorly influenced
by compound 3b, while the other compounds showed a con-
centration-dependent inhibitory eﬀect, 1a and 2b being the
most potent inhibitors of Akt1 activity (IC50 = 19.71 µM and
30.75 µM respectively, Table 1). Compounds 1b and 3a elicited
Scheme 1 (i) Pseudomonas cepacia lipase (Amano PS), Py, TFE-octa-
decanoate or -decanoate, 45 °C, (74–82%); (ii) Ph3CCl, Py, 100 °C,
(70–97%); (iii) hydrazine hydrate, EtOH aq. (45–56%); (iv) TEMPO,
NaClO/NaClO2, CH3CN, 0.67 M phosphate buﬀer (pH 6.7), RT,
(97–98%); (v) DOWEX H+, CH2Cl2 (76–81%).
Scheme 2 (i) TEMPO, NaClO/NaClO2, CH3CN, 0.67 M phosphate
buﬀer (pH 6.7), RT, (43–89%).
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a concentration-dependent inhibition of Akt1, however they
displayed only slight eﬃcacy, even at the maximum concen-
tration: 24% and 39%, respectively. The IC50 values (Table 1)
and the maximal eﬃcacy indicated that the eﬀect is higher for
long than for short acyl chains (1a vs. 1b and 3a vs. 3b) and for
the presence of a second acyl chain (1b vs. 2b, Table 1). These
results are in agreement with other data obtained by our
group.18
The data obtained (Table 1 and Fig. 2) for miltefosine as
well as SDS did not exhibit any significant inhibition of Akt in
the ELISA test (only a very weak inhibition was observed at very
high concentrations, i.e. 500 µM). In contrast, perifosine dis-
played a significant inhibition with an IC50 value of about 40
µM, thus suggesting a specificity for the eﬀect induced by glu-
curonides 1a and 2b and a potency that is comparable with
that of perifosine.
Cellular studies
The antiproliferative activity of the glucuronide compounds
was examined in the IGROV-1 ovarian carcinoma cell line
which is characterized by heterozygous mutation (Het
c.955_958delACTT) of the dual-specificity phosphatase PTEN,
a negative regulator of Akt. A 72 h exposure to the compounds
resulted in a concentration-dependent inhibition of IGROV-1
cell growth for three of the novel glucuronides (Fig. 3). In par-
ticular, the inhibitory eﬀect was evident for compounds 1a
and 2b. In fact, the IC50 values (±SD) were 49.0 ± 7.6 and 156.7
± 23.0 (SD) μM, respectively. The 3a and 3b compounds
induced a slight inhibition of IGROV-1 cell growth after a 72 h
exposure only when a concentration of 300 μM was used.
A modest inhibition of proliferation was also observed when
cells were exposed to the 1b compound, the IC50 value being
around 300 μM. Since the 3a and 3b compounds do not
contain glycerol in their structure, such data suggest that the
presence of glycerol might facilitate growth inhibition (1b vs.
3a). Moreover, long chains seem to enhance the activity
because the 1a compound carries a longer chain than 1b.
Further eﬀort is required to optimize the growth inhibition
properties of this class of compounds. Indeed, an analysis of
inhibition of cell growth in cells exposed for 24 h to the
studied compounds in a serum-free medium indicated an
increased potency for the two active compounds. Under these
conditions, the IC50 values (±SD) of compounds 1a and 2b
were 3.35 ± 0.35 and 9.40 ± 5.0 μM, respectively. This evidence
Fig. 2 PKB1 kinase assay (ELISA) of compounds 1a,b, 2b, 3a,b, miltefo-
sine, perifosine and SDS at the indicated concentrations. Concen-
tration–response (%inhibition) analysis.
Table 1 Compound concentration producing 50% inhibition of PKB1
activity in the ELISA assay
Compound IC50 (µM) 95% confidence intervals
1a 19.71 13.85–28.04
1b >100
2b 30.75 22.91–41.26
3a >100
3b >100
Miltefosine >100
Perifosine 43.35 22.65–83.17
SDS >100
Fig. 3 Cell sensitivity of human ovarian carcinoma cells (IGROV-1) as
evaluated by growth inhibition assays. Cells were seeded and 24 h later
they were exposed to the novel compounds for 72 h. At the end of incu-
bation with the compounds, cells were counted with a cell counter.
Results from a representative experiment are shown.
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raises the possibility that binding of the compounds to serum
components can reduce their cellular uptake or aﬀect their
stability.
To confirm the influence of the serum presence in a
medium on cellular sensitivity towards Akt inhibitors, we also
tested the sensitivity of IGROV-1 cells towards perifosine in the
presence and absence of serum in the medium (Table 2).
Under our experimental conditions, we found that the growth
inhibitory eﬀect of the compound was favored in a serum-free
medium, thus implying that serum aﬀects the stability of peri-
fosine. However, for perifosine a 2.8 fold increase in the anti-
proliferative activity was observed upon incubation in a serum-
free medium; the fold-change for the novel compounds was
higher, implying that they might be less stable or less prone to
accumulate in the cells than perifosine in the presence of
serum.
Conclusions
New glucuronosyldiacylglycerols were prepared and their
inhibitory activity against Akt, both in an isolated enzyme
system and in an ovarian carcinoma cell line, was tested.
The two compounds exhibiting the best target inhibition
activity in a cell-free assay, i.e. compounds 1a and 2b, were
found to be endowed with antiproliferative activity in ovarian
carcinoma cells. Although inhibition of proliferation was
observed, further eﬀorts are needed to increase the potency of
the compounds in in vitro cultured cells. Overall, our data, by
showing a clear modulation of Akt inhibition in relation to
chain length and number, and also to the presence of glycerol
in cell experiments, provide insights into the understanding of
structural features needed to achieve Akt inhibition.
Experimental
Chemical procedures
Materials and equipment. Pseudomonas cepacia lipase (LPS,
lipase PS, specific activity 30.5 triacetin units per mg solid),
from Amano Pharmaceutical Co. (Mitsubishi Italia), was sup-
ported on Celite.24 2-O-(2′,3′,4′,6′-Tetra-O-acetyl-β-D-glucopyra-
nosyl)-sn-glycerol,23a,b 2-O-(2′,3′,4′,6′-tetra-O-chloroacetyl-
β-D-glucopyranosyl)-sn-glycerol,14c 1,3-di-O-octadecanoyl-2-
O-β-D-glucopyranosyl-sn-glycerol (8a),14a decyl β-D-glucurono-
pyranoside (3a),26 octyl β-D-glucuronopyranoside (3b)26,27 and
the acyl carriers (trifluoroethyldecanoate and -octadecanoate)24
were synthesized according to literature procedures. The acidic
Dowex® Marathon™ C sodium form resin was activated by
washing it with 1 M HCl and with distilled water prior to use.
Optical rotations were determined on a Perkin-Elmer 241
polarimeter at 20 °C, in a 1 dm cell. Melting points were
recorded on a Büchi 510 capillary melting point apparatus and
were uncorrected. All reagents and solvents used were of
reagent grade and were purified before use by standard
methods. Dry solvents and liquid reagents were distilled prior
to use or dried on 4 Å molecular sieves. Column chromato-
graphy was carried out on flash silica gel (Merck
230–400 mesh) or by a Biotage Isolera™ Prime flash purifi-
cation system (Biotage-Uppsala, Sweden). TLC analysis was
carried out on a silica gel plate (Merck 60F254) developed with
50% sulfuric acid or an anisaldehyde based reagent. Evapor-
ation under reduced pressure was always eﬀected with a bath
temperature below 40 °C. The structures of all the new syn-
thesized compounds were confirmed through full 1H and 13C
NMR characterization and mass spectroscopy. 1H NMR analy-
sis was performed at 500 MHz with a Bruker FT-NMR
AVANCE™ DRX500 spectrometer using a 5 mm z-PFG (pulsed
field gradient) broadband reverse probe at 298 K unless other-
wise stated, and 13C NMR spectra at 125.76 MHz were recorded
for all the new compounds. The signals were unambiguously
assigned by 2D COSY and HSQC experiments (standard Bruker
pulse program). Chemical shifts were reported as δ (ppm) rela-
tive to residual CHCl3, CH3OD or pyridine fixed at 7.26,
3.30 ppm and 7.19 ppm (higher field signal), respectively, for
1H NMR spectra and relative to CDCl3 fixed at 77.0 ppm
(central line), CD3OD at 49.0 ppm (central line) or pyridine at
123.0 ppm (higher field signal, central line) for 13C NMR
spectra; scalar coupling constants were reported in hertz. Mass
spectra were recorded in negative or positive-ion electrospray
(ESI) mode on a Thermo Quest Finnigan LCQ DECA™ ion trap
mass spectrometer; the mass spectrometer was equipped with
a Finningan ESI interface; sample solutions were injected with
an ionization spray voltage of 4.5 kV or 5.0 kV (positive and
negative-ion mode, respectively), a capillary voltage of 32 V or
−15 V (positive and negative-ion mode, respectively), and a
capillary temperature of 250 °C. Data were processed using the
Finnigan Xcalibur software system. 1H and 13C NMR and MS
analysis confirmed the purity and identity of all synthesized
compounds.
Chemistry
Synthesis of monoesters 1a and 1b
1-O-Acyl-2-O-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-sn-gly-
cerols (4a,b). 2-O-(2′,3′,4′,6′-Tetra-O-acetyl-β-D-glucopyranosyl)-
sn-glycerol23a,b (0.50 g, 1.18 mmol) was dissolved in dry pyri-
dine (5 mL) and trifluoroethyl octadecanoate (2.60 g,
7.10 mmol) and LPS (2.50 g) were added in the order. The sus-
pension was stirred at 45 °C and monitored by TLC (CH2Cl2–
CH3OH 95 : 5 v/v). After 18 h the reaction was stopped and the
Table 2 Sensitivity of IGROV-1 ovarian carcinoma cells to perifosine in
the presence of serum or in serum-free mediuma
FBS IC50 (µM) ±SD
+ 2.21 ± 0.69
− 0.80 ± 0.29
a Cell sensitivity was assessed by growth inhibition assays in which
cells were exposed to perifosine for 72 h in serum (FBS)-containing
medium or for 24 h in serum-free medium. Cells were counted 72 h
after treatment started. IC50 represents the perifosine concentration
producing 50% inhibition of cell growth. The reported values are the
mean ± standard deviation of 3 independent experiments.
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suspension was filtered to remove the enzyme which was
washed with pyridine and methanol. The solvent was evapor-
ated under vacuum and the crude compound was purified by
flash chromatography (hexane–EtOAc from 90 : 10 to 20 : 80,
v/v) to yield 1-O-octadecanoyl-2-O-(2′,3′,4′,6′-tetra-O-acetyl-
β-D-glucopyranosyl)-sn-glycerol (4a) as an amorphous solid
(0.60 g, 0.87 mmol, 74% yield). Mp 95.1–95.4 °C; [α]20D = −4.7
(CHCl3, c 0.5);
1H NMR (CDCl3): δ = 0.87 (t, 3H, J = 7.0 Hz,
CH3), 1.19–1.34 (m, 28H, 14 CH2), 1.61 (m, 2H, CH2), 2.00 (s,
3H, COCH3), 2.03 (s, 3H, COCH3), 2.05 (s, 3H, COCH3), 2.09 (s,
3H, COCH3), 2.30 (t, 2H, J = 7.6 Hz, CH2), 3.58–3.69 (m, 2H,
H-3a and H-3b), 3.76 (ddd, 1H, J5′,6′a = 5.6 Hz, J5′,6′b = 2.6 Hz,
J4′,5′ = 9.7 Hz, H-5′), 3.88 (m, 1H, H-2), 4.05–4.11 (m, 2H, H-1a
and H-1b), 4.16 (dd, 1H, J6′a,6′b = 12.2 Hz, H-6′a), 4.21 (dd, 1H,
H-6′b), 4.61 (d, 1H, J1′,2′ = 8.0 Hz, H-1′), 5.01 (dd, 1H, J2′,3′ =
9.7 Hz, H-2′), 5.05 (dd, 1H, J3′,4′ = 9.7 Hz, H-4′), 5.22 (dd, 1H,
H-3′); 13C-NMR (CDCl3): δ = 14.1 (CH3), 20.5–20.07 (4 COCH3),
22.7 (CH2), 24.9 (CH2), 28.9–30.0 (12 CH2), 31.9 (CH2), 34.1
(CH2), 61.9 (C6′), 62.8 (C3), 63.1 (C1), 68.4 (C4′), 71.2 (C2′), 72.0
(C5′), 72.5 (C3′), 81.5 (C2), 101.2 (C1′), 169.2, 169.4, 170.2,
170.6 and 173.4 (5 CO); ESI-MS (CH3OH, positive-ion mode):
m/z = 711.3 [M + Na]+, calcd for C35H60O13, m/z 688.40 [M]. The
same enzymatic procedure on the same amount of substrate,
using trifluoroethyldecanoate (1.80 g, 7.08 mmol) as the acyl
carrier aﬀorded after flash chromatography (hexane–EtOAc
from 70 : 30 to 30 : 70, v/v) 1-O-decanoyl-2-O-(2′,3′,4′,6′-tetra-O-
acetyl-β-D-glucopyranosyl)-sn-glycerol (4b) as an oil (0.56 g,
0.97 mmol, 82% yield). [α]20D = −1.0 (CHCl3, c 1.0); 1H-NMR
(CDCl3): δ = 0.87 (t, 3H, J = 7.0 Hz, CH3), 1.20–1.35 (m, 12H,
6 CH2), 1.61 (m, 2H, CH2), 2.00 (s, 3H, COCH3), 2.03 (s, 3H,
COCH3), 2.04 (s, 3H, COCH3), 2.09 (s, 3H, COCH3), 2.30 (t, 2H,
J = 7.6 Hz, CH2), 3.57–3.69 (m, 2H, H-3a and H-3b), 3.76 (ddd,
1H, J5′,6′a = 5.6 Hz, J5′,6′b = 2.3 Hz, J4′,5′ = 9.8 Hz, H-5′), 3.88 (m,
1H, H-2), 4.05–4.12 (m, 2H, H-1a and H-1b), 4.16 (dd, 1H, J6′a,6′
b = 12.3 Hz, H-6′a), 4.20 (dd, 1H, H-6′b), 4.61 (d, 1H, J1′,2′ = 8.0
Hz, H-1′), 5.00 (dd, 1H, J2′,3′ = 9.8 Hz, H-2′), 5.04 (dd, 1H, J3′,4′ =
9.8 Hz, H-4′), 5.21 (dd, 1H, H-3′); 13C-NMR (CDCl3): δ = 14.1
(CH3), 20.5–20.7 (4 COCH3), 22.7 (CH2), 24.9 (CH2), 29.0–29.5
(4 CH2), 31.8 (CH2), 34.1 (CH2), 61.9 (C6′), 62.8 (C3), 63.1 (C1),
68.4 (C4′), 71.2 (C2′), 72.0 (C5′), 72.5 (C3′), 81.5 (C2), 101.2
(C1′), 169.2, 169.4, 170.2, 170.6 and 173.4 (5 CO); ESI-MS
(CH3OH, positive-ion mode): m/z = 599.3 [M + Na]
+, calcd for
C27H44O13, m/z 576.28 [M].
1-O-Acyl-3-O-trityl-2-O-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyra-
nosyl)-sn-glycerols (5a,b). Compound 4a (0.47 g, 0.68 mmol)
was dissolved in 5 mL of dry pyridine and trityl chloride
(0.38 g, 1.36 mmol) was added. The reaction mixture was
heated at 100 °C and stirred under argon for 3 h (TLC, hexane–
EtOAc 60 : 40 v/v). The solvent was evaporated under reduced
pressure and the obtained crude compound was submitted to
flash chromatography (hexane–EtOAc 75 : 25, v/v, 1% TEA) to
yield 1-O-octadecanoyl-3-O-trityl-2-O-(2′,3′,4′,6′-tetra-O-acetyl-
β-D-glucopyranosyl)-sn-glycerol (5a) (0.61 g, 0.66 mmol, 97%
yield) as an oil. [α]20D = −3.3 (CHCl3, c 1.0); 1H-NMR (Pyd5): δ =
0.85 (t, 3H, J = 6.5 Hz, CH3), 1.16–1.33 (m, 28H, 14 CH2), 1.64
(m, 2H, CH2), 1.96 (s, 3H, COCH3), 1.99 (s, 3H, COCH3), 2.01
(s, 3H, COCH3), 2.15 (s, 3H, COCH3), 2.35 (t, 2H, J = 7.5 Hz,
CH2), 3.44 (dd, 1H, J3a,2 = 6.0 Hz, J3a,3b = 9.4 Hz, H-3a), 3.57
(dd, 1H, J3b,2 = 5.1 Hz, H-3b), 4.13 (ddd, 1H, J5′,6′a = 2.0 Hz, J5′,6′
b = 4.3 Hz, J4′,5′ = 9.6 Hz, H-5′), 4.33 (dd, 1H, J6′a,6′b = 12.1 Hz,
H-6′a), 4.38 (m, 1H, H-2), 4.49 (dd, 1H, J1a,2 = 5.8 Hz, J1a,1b =
11.6 Hz, H-1a), 4.56 (dd, 1H, H-6′a), 4.58 (dd, 1H, J1b,2 = 3.5
Hz, H-1b), 5.19 (d, 1H, J1′,2′ = 8.0 Hz, H-1′), 5.48 (dd, 1H, J2′,3′ =
9.6 Hz, H-2′), 5.50 (dd, 1H, J3′,4′ = 9.6 Hz, H-4′), 5.77 (dd, 1H,
H-3′), 7.26 (dd, 3H, J = 7.3 Hz, Ph), 7.35 (dd, 6H, J = 7.4 Hz,
Ph), 7.65 (d, 6H, J = 7.8 Hz, Ph); 13C-NMR (Pyd5): δ = 13.8
(CH3), 19.7–20.3 (4 COCH3), 22.4 (CH2), 24.7 (CH2), 28.6–28.8
(12 CH2), 31.6 (CH2), 33.8 (CH2), 62.1 (C6′), 63.4 (C3), 63.5
(C1), 68.7 (C4′), 71.6 (C2′), 71.7 (C5′), 72.9 (C3′), 77.0 (C2), 86.7
(OCPh3), 100.6 (C1′), 127.0 (3 CH, Ph), 127.8 (6 CH, Ph), 128.7
(6 CH, Ph), 144.0 (3 C, Ph), 169.1, 169.3, 169.8, 170.0 and 172.8
(5 CO); ESI-MS (CH3OH, positive-ion mode): m/z = 953.5 [M +
Na]+, calcd for C54H74O13, m/z 930.51 [M].
With the same procedure, starting from 4b (0.51 g,
0.88 mmol), 1-O-decanoyl-3-O-trityl-2-O-(2′,3′,4′,6′-tetra-O-
acetyl-β-D-glucopyranosyl)-sn-glycerol (5b) (0.51 g, 0.62 mmol,
70% yield) was obtained as an oil. [α]20D = −3.4 (CHCl3, c 1.0);
1H-NMR (Pyd5): δ = 0.85 (t, 3H, J = 7.0 Hz, CH3), 1.14–1.30 (m,
12H, 6 CH2), 1.63 (m, 2H, CH2), 1.96 (s, 3H, COCH3), 2.00 (s,
3H, COCH3), 2.01 (s, 3H, COCH3), 2.14 (s, 3H, COCH3), 2.34 (t,
2H, J = 7.5 Hz, CH2), 3.43 (dd, 1H, J3a,2 = 6.0 Hz, J3a,3b = 9.6 Hz,
H-3a), 3.57 (dd, 1H, J3b,2 = 5.2 Hz, H-3b), 4.13 (ddd, 1H, J5′,6′a =
2.5 Hz, J5′,6′b = 4.4 Hz, J4′,5′ = 9.5 Hz, H-5′), 4.33 (dd, 1H,
J6′a,6′b = 12.2 Hz, H-6′a), 4.38 (m, 1H, H-2), 4.49 (dd, 1H, J1a,2 =
6.0 Hz, J1a,1b = 11.6 Hz, H-1a), 4.55 (dd, 1H, H-6′a), 4.58
(dd, 1H, J1b,2 = 3.6 Hz, H-1b), 5.19 (d, 1H, J1′,2′ = 8.0 Hz, H-1′),
5.48 (dd, 1H, J2′,3′ = 9.5 Hz, H-2′), 5.51 (dd, 1H, J3′,4′ = 9.5 Hz,
H-4′), 5.77 (dd, 1H, H-3′), 7.26 (dd, 3H, J = 7.3 Hz, Ph),
7.35 (dd, 6H, J = 7.4 Hz, Ph), 7.64 (d, 6H, J = 7.8 Hz, Ph);
13C-NMR (Pyd5): δ = 13.8 (CH3), 19.6–20.4 (4 COCH3), 22.4
(CH2), 24.7 (CH2), 28.4–29.6 (4 CH2), 31.6 (CH2), 33.8 (CH2),
62.0 (C6′), 63.4 (C3), 63.5 (C1), 68.7 (C4′), 71.6 (C2′), 71.7 (C5′),
72.9 (C3′), 77.0 (C2), 86.6 (OCPh3), 100.6 (C1′), 127.0 (3 CH,
Ph), 127.8 (6 CH, Ph), 128.7 (6 CH, Ph), 144.0 (3 C, Ph), 169.1,
169.3, 169.8, 170.0 and 172.8 (5 CO); ESI-MS (CH3OH, positive-
ion mode): m/z = 841.3 [M + Na]+, calcd for C46H58O13, m/z
818.39 [M].
1-O-Acyl-3-O-trityl-2-O-β-D-glucopyranosyl-sn-glycerols (6a,b).
Compound 5a (0.60 g, 0.64 mmol) was dissolved in 6.4 mL of
aq. ethanol (85%). Hydrazine mono-hydrate (0.32 g, 6.4 mmol)
was added and the reaction mixture was stirred at 45 °C over-
night (TLC, CH2Cl2–CH3OH 95 : 5 v/v). The solvent was evapor-
ated under a stream of N2 and the crude compound was
purified by flash chromatography (CH2Cl2–CH3OH 95 : 5, v/v)
to yield 1-O-octadecanoyl-3-O-trityl-2-O-β-D-glucopyranosyl-sn-
glycerol (6a) (0.22 g, 0.29 mmol, 45% yield) as an oil: [α]20D =
+6.3 (CHCl3, c 1.0);
1H-NMR (Pyd5): δ = 0.85 (t, 3H, J = 7.0 Hz,
CH3), 1.15–1.31 (m, 28H, 14 CH2), 1.61 (m, 2H, CH2), 2.32 (m,
2H, CH2), 3.54 (dd, 1H, J3a,2 = 6.6 Hz, J3a,3b = 9.4 Hz, H-3a),
3.66 (dd, 1H, J3b,2 = 4.7 Hz, H-3b), 3.92 (m, 1H, H-5′), 3.99 (m,
1H, H-2′), 4.19–4.27 (m, 2H, H-3′and H-4′), 4.34 (m, 1H, H-6′a),
4.46 (m, 1H, H-6′b), 4.49 (m, 1H, H-2), 4.66–4.72 (m, 2H, H-1a
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and H-1b), 5.04 (d, 1H, J1′,2′ = 7.7 Hz, H-1′), 7.23 (dd, 3H, J = 7.3
Hz, Ph), 7.32 (dd, 6H, J = 7.4 Hz, Ph), 7.64 (d, 6H, J = 7.8 Hz,
Ph); 13C-NMR (Pyd5): δ = 13.8 (CH3), 22.4 (CH2), 24.7 (CH2),
28.8–29.7 (12 CH2), 31.6 (CH2), 33.9 (CH2), 62.4 (C6′), 63.7
(C3), 63.8 (C1), 71.2 (C3′ or C4′), 74.7 (C2′), 76.0 (C2), 77.9 (C3′
or C4′ and C5′), 86.6 (OCPh3), 104.3 (C1′), 126.9 (3 CH, Ph),
127.8 (6 CH, Ph), 128.7 (6 CH, Ph), 144.2 (3 C, Ph), 173.0 (CO);
ESI-MS (CH3OH, positive-ion mode): m/z = 785.3 [M + Na]
+,
calcd for C46H66O9, m/z 762.47 [M].
With the same procedure staring from 5b (0.47 g,
0.58 mmol) 1-O-decanoyl-3-O-trityl-2-O-β-D-glucopyranosyl-sn-
glycerol (6b) (0.21 g, 0.32 mmol, 56% yield) was obtained as an
oil: [α]20D = +7.8 (CHCl3, c 1.0);
1H-NMR (Pyd5): δ = 0.83 (t, 3H,
J = 7.0 Hz, CH3), 1.07–1.28 (m, 12H, 6 CH2), 1.60 (m, 2H, CH2),
2.31 (m, 2H, CH2), 3.54 (dd, 1H, J3a,2 = 6.5 Hz, J3a,3b = 9.4 Hz,
H-3a), 3.66 (dd, 1H, J3b,2 = 4.7 Hz, H-3b), 3.92 (m, 1H, H-5′),
3.98 (m, 1H, H-2′), 4.18–4.26 (m, 2H, H-3′and H-4′), 4.33 (dd,
1H, J5′,6′a = 4.9 Hz, J6′a,6′b = 11.5 Hz, H-6′a), 4.45 (dd, 1H, J5′,6′ab
= 2.2 Hz, H-6′b), 4.49 (m, 1H, H-2), 4.65–4.71 (m, 2H, H-1a and
H-1b), 5.03 (d, 1H, J1′,2′ = 7.7 Hz, H-1′), 7.23 (dd, 3H, J = 7.3 Hz,
Ph), 7.32 (dd, 6H, J = 7.4 Hz, Ph), 7.63 (d, 6H, J = 7.8 Hz, Ph);
13C-NMR (Pyd5): δ = 13.8 (CH3), 22.4 (CH2), 24.7 (CH2),
28.7–29.3 (4 CH2), 31.5 (CH2), 33.8 (CH2), 62.4 (C6′), 63.7 (C3),
63.8 (C1), 71.2 (C3′ or C4′), 74.7 (C2′), 76.0 (C2), 77.9 (C3′ or
C4′ and C5′), 86.6 (OCPh3), 104.3 (C1′), 126.9 (3 CH, Ph), 127.8
(6 CH, Ph), 128.7 (6 CH, Ph), 144.2 (3 C, Ph), 173.0 (CO);
ESI-MS (CH3OH, positive-ion mode): m/z = 673.2 [M + Na]
+,
calcd for C38H50O9, m/z 650.35 [M].
1-O-Acyl-3-O-trityl-2-O-β-D-glucuronopyranosyl-sn-glycerols (7a,
b). To a solution of compound 6a (0.22 g, 0.29 mmol) in a
55 : 45 mixture of CH3CN and 0.67 M phosphate buﬀer (3 mL,
pH 6.7), TEMPO (0.01 g, 0.061 mmol), NaClO2 (20% aqueous
solution, 0.4 mL) and NaClO2 (15% aqueous solution,
0.025 mL) were added in the order. After stirring for 3 hours
(TLC, CH2Cl2–CH3OH 90 : 10 v/v), acetonitrile was removed
under reduced pressure and the aqueous phase was extracted
with Et2O. The organic layers were assembled, dried over anhy-
drous Na2SO4, filtered and evaporated to give the desired 1-O-
octadecanoyl-3-O-trityl-2-O-β-D-glucuronopyranosyl-sn-glycerol
(7a) (0.22 g, 0.28 mmol, 97% yield) as an amorphous solid.
Mp: 98–99 °C; [α]20D = −11.1 (CHCl3–CH3OH 65 : 35, c 1.0);
1H-NMR (Pyd5): δ = 0.85 (t, 3H, J = 7.0 Hz, CH3), 1.13–1.35 (m,
28H, 14 CH2), 1.59 (m, 2H, CH2), 2.28 (m, 2H, CH2), 3.56 (dd,
1H, J3a,2 = 6.6 Hz, J3a,3b = 9.2 Hz, H-3a), 3.68 (dd, 1H, J3b,2 = 4.4
Hz, H-3b), 4.03 (dd, J1′,2′ = 7.6 Hz, J2′,3′ = 8.0 Hz, 1H, H-2′), 4.25
(m, 1H, H-3′), 4.32–4.42 (m, 2H, H-4′ and H-5′), 4.54 (m, 1H,
H-2), 4.60–4.71 (m, 2H, H-1a and H-1b), 5.06 (d, 1H, H-1′),
7.19 (dd, 3H, J = 7.4 Hz, Ph), 7.31 (dd, 6H, J = 7.4 Hz, Ph),
7.63 (d, 6H, J = 7.8 Hz, Ph); 13C-NMR (Pyd5): δ = 13.8 (CH3),
22.4 (CH2), 24.7 (CH2), 28.8–29.7 (12 CH2), 31.6 (CH2),
33.8 (CH2), 63.5 (C1 and C3), 73.1 (C4′ or C5′), 74.4 (C2′),
75.5 (C2), 76.5 (C4′ or C5′), 77.6 (C3′), 86.6 (OCPh3), 103.7
(C1′), 126.8 (3 CH, Ph), 127.8 (6 CH, Ph), 128.7 (6 CH, Ph),
144.1 (3 C, Ph), 173.0 (CO), 174.3 (CO); ESI-MS (CH3OH, nega-
tive-ion mode): m/z = 775.5 [M − 1]−, calcd for C46H64O10, m/z
776.45 [M].
With the same procedure, starting from 6b (0.21 g,
0.32 mmol), 1-O-decanoyl-3-O-trityl-2-O-β-D-glucuronopyrano-
syl-sn-glycerol (7b) (0.21 g, 0.31 mmol, 98% yield) was obtained
as an amorphous solid. Mp: 154–155 °C; [α]20D = −11.3 (CHCl3–
CH3OH 65 : 35, c 1.0);
1H-NMR (Pyd5): δ = 0.84 (t, 3H, J = 7.0
Hz, CH3), 1.07–1.28 (m, 12H, 6 CH2), 1.57 (m, 2H, CH2), 2.26
(m, 2H, CH2), 3.56 (dd, 1H, J3a,2 = 6.6 Hz, J3a,3b = 9.0 Hz, H-3a),
3.64 (dd, 1H, J3b,2 = 4.2 Hz, H-3b), 3.99 (dd, J1′,2′ = 7.8 Hz, J2′,3′ =
8.5 Hz, 1H, H-2′), 4.16–4.27 (m, 3H, H-3′, H-4′ and H-5′), 4.57
(m, 1H, H-2), 4.65 (dd, 2H, J1′a,2 = 4.8 Hz, J1′a, 1′b = 11.5 Hz,
H-1a), 4.70 (dd, 2H, J1′b,2 = 4.0 Hz, H-1b), 5.00 (d, 1H, H-1′),
7.20 (dd, 3H, J = 7.4 Hz, Ph), 7.31 (dd, 6H, J = 7.4 Hz, Ph), 7.62
(d, 6H, J = 7.8 Hz, Ph); 13C-NMR (Pyd5): δ = 13.8 (CH3), 22.4
(CH2), 24.6 (CH2), 28.7–29.3 (4 CH2), 31.5 (CH2), 33.8 (CH2),
63.2 (C1), 63.4 (C3), 73.2 (C4′ or C5′), 74.3 (C2′), 74.9 (C2), 76.0
(C4′ or C5′), 77.7 (C3′), 86.6 (OCPh3), 103.1 (C1′), 126.8 (3 CH,
Ph), 127.8 (6 CH, Ph), 128.7 (6 CH, Ph), 144.1 (3 C, Ph), 173.0
(CO), 175.6 (CO); ESI-MS (CH3OH, negative-ion mode): m/z =
663.2 [M − 1]−, calcd for C38H48O10, m/z 664.32 [M].
1-O-acyl-2-O-β-D-glucuronopyranosyl-sn-glycerols (1a,b). Com-
pound 7a (0.11 g, 0.14 mmol) was dissolved in CH2Cl2
(1.5 mL) and Dowex® Marathon™ C, H+ form (0.15 g), was
added (methanol washing of the resin was not done, see
Materials and equipment, to avoid methyl ester formation).
The reaction was stirred overnight at room temperature (TLC,
CH2Cl2–CH3OH 90 : 10 v/v) obtaining a white suspension. The
reaction mixture was filtered and the residue was washed with
CH2Cl2 which was eliminated. The remaining solid was then
washed with AcOEt and the washings were dried over Na2SO4
and evaporated under reduced pressure yielding the desired
pure 1-O-octadecanoyl-2-O-β-D-glucuronopyranosyl-sn-glycerol
(1a) (0.06 g, 0.11 mmol, 76% yield) as a white solid. Mp:
127–128 °C; [α]20D = −29.3 (CHCl3–CH3OH 65 : 35, c 0.5);
1H-NMR (Pyd5): δ = 0.85 (t, 3H, J = 7.0 Hz, CH3), 1.13–1.31 (m,
28H, 14 CH2), 1.64 (m, 2H, CH2), 2.37 (m, 2H, CH2), 4.10 (dd,
J1′,2′ = 7.8 Hz, J2′,3′ = 8.9 Hz, 1H, H-2′), 4.16 (dd, 1H, J3a,2 = 5.5
Hz, J3a,3b = 11.5 Hz, H-3a), 4.23 (dd, 1H, J3b,2 = 4.9 Hz, H-3b),
4.33 (dd, 1H, J3′,4′ = 8.9 Hz, H-3′), 4.52 (m, 1H, H-2), 4.60 (dd,
1H, J4′,5′ = 8.9 Hz, H-4′), 4.66 (d, 1H, H-5′), 4.69–4.77 (m, 2H,
H-1a and H-1b), 5.22 (d, 1H, H-1′); 13C-NMR (Pyd5): δ = 13.8
(CH3), 22.4 (CH2), 24.7 (CH2), 28.8–29.5 (12 CH2), 31.6 (CH2),
33.9 (CH2), 62.2 (C3), 63.9 (C1), 72.9 (C4′), 74.3 (C2′), 77.3 (C3′
and C5′), 78.7 (C2), 104.5 (C1′), 172.1 (CO), 173.1 (CO); ESI-MS
(CH3OH, negative-ion mode): m/z = 533.3 [M − 1]−, calcd for
C27H50O10, m/z 534.34 [M].
With the same procedure, starting with 7b (0.14 g,
0.21 mmol) and washing the residue with AcOEt–iPrOH 1 : 1,
1-O-decanoyl-2-O-β-D-glucuronopyranosyl-sn-glycerol (1b)
(0.07 g, 0.17 mmol, 81% yield) was obtained as a white sticky
solid. [α]20D = −31.6 (CHCl3–CH3OH 65 : 35, c 1.0); 1H-NMR
(Pyd5): δ = 0.82 (t, 3H, J = 7.0 Hz, CH3), 1.09–1.27 (m, 12H, 6
CH2), 1.62 (m, 2H, CH2), 2.36 (m, 2H, CH2), 4.09 (dd, J1′,2′ = 7.8
Hz, J2′,3′ = 8.4 Hz, 1H, H-2′), 4.15 (dd, 1H, J3a,2 = 5.5 Hz, J3a,3b =
11.4 Hz, H-3a), 4.21 (dd, 1H, J3b,2 = 4.8 Hz, H-3b), 4.32 (dd, 1H,
J3′,4′ = 8.9 Hz, H-3′), 4.51 (m, 1H, H-2), 4.58 (dd, 1H, J4′,5′ = 8.9
Hz, H-4′), 4.64 (d, 1H, H-5′), 4.68–4.76 (m, 2H, H-1a and H-1b),
Paper Organic & Biomolecular Chemistry
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5.20 (d, 1H, H-1′); 13C-NMR (Pyd5): δ = 13.7 (CH3), 22.4 (CH2),
24.7 (CH2), 28.7–29.2 (4 CH2), 31.5 (CH2), 33.8 (CH2), 62.2 (C3),
63.8 (C1), 72.8 (C4′), 74.3 (C2′), 77.2 (C5′), 77.3 (C3′), 78.7 (C2),
104.5 (C1′), 172.1 (CO), 173.1 (CO); ESI-MS (CH3OH, negative-
ion mode): m/z = 421.5 [M − 1]−, Calcd for C19H34O10, m/z
422.22 [M].
Configuration assignment of compound 4a
Compound 4a (0.027 g, 0.04 mmol) was dissolved in dry pyri-
dine (1 mL) and acetic anhydride (0.5 g, 4.9 mmol) was added.
The reaction was stirred at room temperature and stopped
after 3 hours (TLC, hexane–EtOAc 60 : 40 v/v). After the usual
work-up the crude compound was purified by flash chromato-
graphy (hexane–EtOAc 70 : 30 v/v) and the obtained pure com-
pound (0.024 g, 0.033 mmol, 82% yield) resulted to be
identical to the known 1-O-octadecanoyl-3-O-acetyl-2-O-
(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-sn-glycerol.24 Oil;
[α]20D = −8.7 (CHCl3, c 1); 1H NMR (CDCl3): δ = 0.86 (t, 3H, J =
7.0 Hz, CH3), 1.19–1.33 (m, 28H, 14 CH2), 1.59 (m, 2H, CH2),
1.98 (s, 3H, COCH3), 2.00 (s, 3H, COCH3), 2.01 (s, 3H, COCH3),
2.04 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 2.29 (t, 2H, J = 7.6
Hz, CH2), 3.67 (ddd, 1H, J5′,6′a = 2.4 Hz, J5′,6′b = 5.1 Hz, J4′,5′ =
10.0 Hz, H-5′), 4.04 (m, 1H, H-2), 4.06–4.20 (m, 5H, H-1a, H-1b,
H-3a, H-3b and H-6′a), 4.22 (dd, 1H, J6′a,6′b = 12.3 Hz, H-6′b),
4.61 (d, 1H, J1′,2′ = 7.9 Hz, H-1′), 4.96 (dd, 1H, J2′,3′ = 9.6 Hz,
H-2′), 5.04 (dd, 1H, J3′,4′ = 9.6 Hz, H-4′), 5.17 (dd, 1H, H-3′);
13C-NMR (CDCl3): δ = 14.1 (CH3), 20.4–20.08 (5 COCH3), 22.7
(CH2), 24.8 (CH2), 28.9–29.9 (12 CH2), 31.9 (CH2), 34.1 (CH2),
62.0 (C6′), 63.1 (C1), 63.3 (C3), 68.4 (C4′), 71.3 (C2′), 71.9 (C5′),
72.7 (C3′), 75.6 (C2), 100.8 (C1′), 169.1, 169.3, 170.2, 170.5,
170.6 and 173.3 (6 CO); ESI-MS (CH3OH, positive-ion mode):
m/z = 753.5 [M + Na]+, calcd for C37H62O14, m/z 730.41 [M].
Synthesis of diesters 2a and 2b
1,3-Di-O-octadecanoyl-2-O-β-D-glucuronopyranosyl-sn-glycerol
(2a). 1,3-Di-O-octadecanoyl-2-O-β-D-glucopyranosyl-sn-glycerol
8a14a (0.055 g, 0.07 mmol) was suspended in 1 mL of a
55 : 45 mixture of CH3CN and 0.67 M phosphate buﬀer (pH
6.7) and TEMPO (0.008 g, 0.05 mmol), NaClO2 (20% aqueous
solution, 0.3 mL) and NaClO (15% aqueous solution,
0.015 mL) were added. After stirring overnight at room temp-
erature (TLC, CH2Cl2–CH3OH 90 : 10 v/v), 0.5 M Na2S2O3 was
added and the aqueous phase was acidified with HCl and
extracted with Et2O. The organic layers were assembled, dried
over anhydrous Na2SO4, filtered and evaporated under reduced
pressure to give 1,3-di-O-octadecanoyl-2-O-β-D-glucuronopyra-
nosyl-sn-glycerol (2a) (0.024 g, 0.03 mmol, 43% yield)14b as a
white solid. Mp: 158–159 °C. 1H-NMR (CDCl3–CD3OD–D2O,
65 : 35 : 6, 315 K): δ = 0.82–0.87 (m, 6H, 2 CH3), 1.18–1.31 (m,
56H, 28 CH2), 1.53–1.61 (m, 4H, 2 CH2), 2.27–2.32 (m, 4H,
2 CH2), 3.24 (dd, 1H, J1′,2′ = 7.8 Hz, J2′,3′ = 9.1 Hz, H-2′), 3.42
(dd, 1H, J3′,4′ = 9.0 Hz, H-3′), 3.45 (dd, 1H, J4′,5′ = 9.5 Hz, H-4′),
3.56 (d, 1H, H-5′), 4.17–4.23 (m, 4H, H-2, H-1a, H-3a, and H-1b
or H-3b), 4.30 (m, 1H, H-1b or H-3b), 4.41 (d, 1H, H-1′);
13C-NMR (CDCl3–CD3OD–D2O, 65 : 35 : 6, 315 K): δ = 14.3
(2 CH3), 23.1 (2 CH2), 25.3 (2 CH2), 29.5–30.2 (24 CH2), 32.4
(2 CH2), 34.6 (2 CH2), 63.2 (C1 or C3), 64.0 (C1 or C3), 72.5
(C4′), 73.8 (C2′), 75.2 (C2), 75.6 (s, C5′), 76.6 (C3′), 103.2 (C1′),
174.8 (2 CO); ESI-MS (CH3OH, negative-ion mode): m/z = 799.7
[M − 1]−, Calcd for C45H84O11, m/z 800.60 [M].
1,3-Di-O-decanoyl-2-O-β-D-glucopyranosyl-sn-glycerol (8b). 2-O-
(2,3,4,6-Tetra-O-chloroacetyl-β-D-glucopyranosyl)-sn-glycerol14c
(0.26 g, 0.47 mmol) was dissolved in dry CH2Cl2 (2.5 mL) and
cooled at −10 °C. Decanoyl chloride (0.22 g, 1.18 mmol) as a
15% (v/v) CH2Cl2 solution and pyridine (0.23 mL, 2.8 mmol)
as a 10% (v/v) CH2Cl2 solution were added in the order and
the mixture was stirred at −10 °C under an Ar atmosphere. The
reaction was monitored by TLC (petroleum ether–EtOAc,
70 : 30 v/v) and stopped after 50 min diluting with CH2Cl2
(15 mL). The solution was washed with 1 M HCl (10 mL), water
(10 mL), NaHCO3 saturated solution (10 mL), and water (2 ×
10 mL) in the order and the aqueous phases were re-extracted
with CH2Cl2 (2 × 15 mL). The collected organic layers were
dried over Na2SO4, evaporated under reduced pressure and the
crude residue was submitted to flash chromatography (pet-
roleum ether–EtOAc 80 : 20 v/v) aﬀording 1,3-di-O-decanoyl-2-
O-(2′,3′,4′,6′-tetra-O-chloroacetyl-β-D-glucopyranosyl)-sn-glycerol
(0.24 g, 0.28 mmol, 60% yield), oil. [α]20D = −3.3 (CHCl3, c 1.0);
1H-NMR (CDCl3): δ = 0.85–0.90 (m, 6H, 2 CH3), 1.20–1.34 (m,
24H, 12 CH2), 1.56–1.64 (m, 4H, 2 CH2), 2.27–2.33 (m, 4H,
2 CH2), 3.83 (ddd, 1H, J5′,6′a = 2.5 Hz, J5′,6′b = 5.1 Hz, J4′,5′ = 10.0
Hz, H-5′), 3.98 (s, 2H, ClCH2), 4.01 (m, 2H, ClCH2), 4.04 (m, 2H,
ClCH2), 4.05–4.27 (m, 5H, H-1a, H-1b, H-3a, H-3b and H-2), 4.14
(s, 2H, ClCH2), 4.29 (dd, 1H, J6′a,5′ = 2.5 Hz, J6′a,6′b = 12.3 Hz,
H-6′a), 4.36 (dd, 1H, J6′b,5′ = 5.1 Hz, H-6′b), 4.72 (d, 1H, J1′,2′ = 7.9
Hz, H-1′), 5.05 (dd, 1H, J2′,3′ = 9.6 Hz, H-2′), 5.14 (dd, 1H, J3′,4′ =
9.6 Hz, H-4′), 4.32 (dd, 1H, H-3′); 13C-NMR (CDCl3): δ = 14.1
(2 CH3), 22.6 (2 CH2), 24.8 (2 CH2), 29.1–29.4 (8 CH2), 31.8
(2 CH2), 34.0 (CH2), 34.1 (CH2), 40.1, 40.2, 40.3 and 40.5
(4 CH2Cl), 62.7 (C1 and C3), 63.1 (C6′), 69.6 (C4′), 71.3 (C5′),
72.2 (C2′), 73.7 (C3′), 75.9 (C2), 100.2 (C1′), 165.9, 166.2, 166.9,
167.0 (4 CO), 173.4 (2 CO); ESI-MS (CH3OH, negative-ion mode):
m/z = 867.1 [M − 1]−, Calcd for C37H58Cl4O14, m/z 868.25 [M].
The obtained didecanoate (0.23 g, 0.26 mmol) was dis-
solved in EtOAc–CH3OH (7 mL, 1 : 1 v/v) and hydrazine acetate
(0.366 g, 3.98 mmol) was added. The reaction was stirred
under an Ar atmosphere at room temperature overnight and
monitored by TLC (CH2Cl2–CH3OH, 95 : 5 v/v). The solvent was
evaporated under reduced pressure and the crude residue was
subjected to repeated flash column chromatography (CH2Cl2–
CH3OH, 95 : 5–90 : 10 v/v) followed by recrystallization from
ethanol to remove hydrazine impurities yielding pure 1,3-di-O-
decanoyl-2-O-β-D-glucopyranosyl-sn-glycerol (8b) (0.063 g,
0.11 mmol, 43% yield) as a white solid. Mp: 85 °C (from
ethanol); [α]20D = −8.2 (CHCl3, c 1.0); 1H-NMR (CDCl3): δ =
0.86–0.91 (m, 6H, 2 CH3), 1.19–1.35 (m, 24H, 12 CH2),
1.56–1.65 (m, 4H, 2 CH2), 2.28–2.37 (m, 4H, 2 CH2), 3.32–3.44
(m, 2H, H-2′ and H-5′), 3.51–3.58 (m, 2H, H-3′ and H-4′), 3.78
(m, 1H, H-6′a), 3.89 (m, 1H, H-6′b), 4.04 (m, 1H, H-2),
4.14–4.22 (m, 2H, H-1a and H-3a), 4.27 (dd, 1H, J1b/3b,2 =
5.0 Hz, J1b/3b,1a/3a = 11.5 Hz, H-1b or H-3b), 4.35 (dd, 1H,
J1b/3b,2 = 3.8 Hz, J1b/3b,1a/3a = 11.8 Hz, H-1b or H-3b), 4.41 (d, 1H,
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J1′,2′ = 7.7 Hz, H-1′);
13C-NMR (CDCl3): δ = 14.1 (2 CH3), 22.7
(2 CH2), 24.8 (2 CH2), 29.1–29.4 (8 CH2), 31.8 (2 CH2), 34.1
(CH2), 34.2 (CH2), 62.3 (C6′), 63.1 (C1 and C3), 70.1 (C3′ or C4′),
73.5 (C2′), 75.8 (C5′), 76.0 (C2), 76.2 (C3′ or C4′), 103.3 (C1′),
173.7 (CO), 174.1 (CO). ESI-MS (CH3OH, positive-ion mode): m/z
= 585.4 [M + Na]+, calcd for C29H54O10, m/z 562.37 [M].
1,3-Di-O-decanoyl-2-O-β-D-glucuronopyranosyl-sn-glycerol (2b).
Starting from 8b (0.05 g, 0.09 mmol), with the same procedure
as reported above for 2a, 1,3-di-O-decanoyl-2-O-β-D-glucurono-
pyranosyl-sn-glycerol (2b) (0.046 g, 0.08 mmol, 89% yield) was
obtained as an oil. [α]20D = −18.9 (CH3OH, c 1.0); 1H-NMR
(CD3OD): δ = 0.85–0.92 (m, 6H, 2 CH3), 1.22–1.36 (m, 24H, 12
CH2), 1.54–1.64 (m, 4H, 2 CH2), 2.29–2.37 (m, 4H, 2 CH2), 3.32
(dd, 1H, J1′,2′ = 8.0 Hz, J2′,3′ = 8.5 Hz, H-2′), 3.41 (dd, 1H, J3′,4′ =
9.0 Hz, H-3′), 3.47 (dd, 1H, J4′,5′ = 9.0 Hz, H-4′), 3.65 (br d, 1H,
H-5′), 4.19–4.26 (m, 4H, H-2, H-1a, H-3a, and H-1b or H-3b),
4.31 (m, 1H, H-1b or H-3b), 4.46 (d, 1H, H-1′); 13C-NMR
(CD3OD): δ = 14.5 (2 CH3), 23.7 (2 CH2), 26.0 (2 CH2), 30.2–30.6
(8 CH2), 33.1 (2 CH2), 34.9 (2 CH2), 63.9 (C1 or C3), 64.7 (C1 or
C3), 73.5 (C4′), 74.8 (C2′), 75.9 (C2), 76.4 (s, C5′), 77.6 (C3′),
104.3 (C1′), 175.1 (CO), 175.2 (CO), 176.9 (br s, CO); ESI-MS
(CH3OH, negative-ion mode): m/z = 575.3 [M − 1]−, Calcd for
C29H52O11, m/z 576.35 [M].
Akt inhibition assays
Akt1 ELISA activity assay. The inhibitory activity of com-
pounds 1a–b, 2b, 3a–b, miltefosine (Sigma), perifosine (Sigma)
and SDS (Sigma) was tested employing the CycLex AKT/PKB
kinase Assay/Inhibitor Screening Kit (CycLex, Eppendorf,
Milano, Italy). Plates were pre-coated with “AKTide-2T” which
can be eﬃciently phosphorylated by Akt1. The detector anti-
body specifically detects the phosphorylated “AKTide-2T”. Par-
ticularly, to perform the test, samples 1a–b, 2b, 3a–b and SDS
were dissolved in DMSO (note that 2a was insoluble in this
solvent), and miltefosine and perifosine in water. The prepared
solutions were then diluted in kinase buﬀer to a final concen-
tration of 500, 100, 50, 10 and 1 µM, respectively. Compounds
were added together with the constitutive active form of
human Akt1 (25 m units per well), and allowed to phosphory-
late the bound substrate following the addiction of Mg2+ and
ATP. The amount of phosphorylated substrate was measured
by binding it with the horseradish peroxidase conjugate of
an anti-phospho-AKTide-2T monoclonal antibody, which then
catalyzes the conversion of the chromogenic substrate tetra-
methylbenzidine from the colourless reduced form to the
yellow oxidized product, after the addition of the stopping
reagent. The absorbance of the resulting solution is deter-
mined spectrophotometrically at λ = 450 nm, and it is related
to Akt1 activity in the tested solution. Staurosporine (Sigma-
Aldrich, Milano, Italy) at the final concentration of 1 µM was
employed as the “inhibitor control” as indicated in the assay
protocol. Each experiment was performed in triplicate.
Cellular studies
Compound preparation. Perifosine was dissolved in H2O at
20 mM. All tested compounds were easily dissolved in 100%
DMSO at 50 mM. Cell culture and cell growth assay: the human
ovarian carcinoma IGROV-1 cell line30 was grown in
RPMI-1640 medium supplemented with 10% fetal bovine
serum at 37 °C under 5% CO2 atmosphere. For cell growth
inhibition assays, cells were plated in 12-well plates at 10 000
cells cm−2 in a complete medium. The day after seeding, cells
were exposed to the solvent (DMSO) or to diﬀerent concen-
trations of the novel compounds for 72 h. For tests in a serum-
free medium, the day after seeding complete medium was sub-
stituted with a serum-free medium and the cells were exposed
to the compounds. Twenty-four hours later the drug-contain-
ing medium was replaced with a complete medium. Cells were
harvested using trypsin and counted 96 h after seeding using
a Coulter Counter (Z1, Beckman Coulter). Each experiment
was performed three times. The percentages of inhibition in
drug-treated versus solvent-treated samples are reported in
dose–response curves. IC50 represents the drug concentration
inhibiting growth by 50%.
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